Nurix Therapeutics (NRIX) closed at $22.21 on Oct 8, 2026, down 2.3% on the day. The stock is down 15.4% over the past month, down 3.7% over three months, up 17.1% year to date and up 125.9% over the past year. It trades 21.3% below its 52-week high of $28.23 and 123.8% above its 52-week low of $9.93. The close sits below its 50-day moving average ($25.20) and above its 200-day moving average ($19.67).
Over its last 8 reports the stock moved an average of 3.4% on the first trading day after earnings, beating the options-implied move in 0 of 6.
Over the last 8 reports, NRIX moved an average of 3.4% on the first trading day after earnings. The move beat the options-implied move in 0 of 6 reports.
Yes — the Oct 8, 2026 close of $22.21 is 12.9% above the 200-day average of $19.67.
NRIX closed 21.3% below its 52-week high of $28.23.
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
